REMARKS/ARGUMENTS

Claims 1-5 are active.

Claim 1 is limited to enterolactone (ENL), which the Examiner has indicated as being suitably described by the specification. See page 2 of the Action. Accordingly, the written description rejection is no longer applicable.

Claims 3 and 4 have been amended to remove the multiple dependency.

No new matter is added.

The rejection of Claims 1-5 under 35 USC 102(b) citing Ahoptupa in view of Pezzuto is no longer applicable. While Ahotupa teaches that HMR is a precursor to the ENL metabolite Ahotupa does not describe or suggest a composition specifically with ENL specified in Claim 1. Indeed, Ahotupa describes compositions for administration to a person that comprises hydromatairesinol (HMR), isomers, stereoisomers and salts thereof.

Accordingly, Ahoptupa does not anticipate the claims pending in this application. Withdrawal of the rejection is requested.

A Notice of Allowance for all pending claims is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, L.L.P.

Daniel J. Pereira Attorney of Record Registration No. 45,518

 $\begin{array}{c} \text{Customer Number} \\ 22850 \end{array}$

Tel: (703) 413-3000 Fax: (703) 413 -2220 (OSMMN 07/09)